{"id":33231,"date":"2024-07-03T14:56:10","date_gmt":"2024-07-03T18:56:10","guid":{"rendered":"https:\/\/avalere.com\/?p=33231"},"modified":"2024-10-03T15:07:28","modified_gmt":"2024-10-03T19:07:28","slug":"an-access-path-for-digital-therapeutics","status":"publish","type":"post","link":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics","title":{"rendered":"An Access Path for Digital Therapeutics"},"content":{"rendered":"<p>While there has been substantial investment in and focus on the digital health sector, patient access to digital therapeutics (DTx) remains hindered by <a href=\"https:\/\/advisory.avalerehealth.com\/insights\/bio-international-convention-insights-patient-assistance-and-digital-therapeutics\">numerous obstacles<\/a>, such as regulatory and reimbursement complexities, which ultimately slow progress for improving access. While reimbursement barriers exist for digital therapeutics, ongoing legislative efforts, development of private payer frameworks, and programs such as the Public Health Informatics and Technology Act are shaping a more <a href=\"https:\/\/advisory.avalerehealth.com\/insights\/manufacturers-opportunities-in-digital-therapeutics\">supportive environment<\/a> for DTx.<\/p>\n<p>In the <em>Med Ad News<\/em> article, \u201cForging an Access Pathway for Digital Therapeutics,\u201d Brigit Kyei-Baffour discusses the effort to simplify clinician prescription processes and enhance patient access. She also describes innovative approaches that explore new payment and evaluation models that drive innovation in healthcare delivery.<\/p>\n<p>To read the full article, visit Med Ad News&#8217; blog, <a href=\"https:\/\/www.pharmalive.com\/forging-an-access-pathway-for-digital-therapeutics\/\">PharmaLive.com<\/a>.<\/p>\n<p><strong>Learn More<\/strong><br \/>\nAvalere works closely with manufacturers and payers to evaluate, develop, and refine <a href=\"https:\/\/advisory.avalerehealth.com\/offering\/patient-access-and-support-services\">patient support programs<\/a> that are finely attuned to the current policy and market landscape. We also collaborate with digital therapeutics and <a href=\"https:\/\/advisory.avalerehealth.com\/digital-health\">digital health<\/a> stakeholders to maximize patient access and affordability. To learn more about how Avalere can assist you, <em><a href=\"https:\/\/pages.avalere.com\/Insights.html\">connect with us<\/a><\/em>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>While there has been substantial investment in and focus on the digital health sector, patient access to digital therapeutics (DTx) remains hindered by numerous obstacles, such as regulatory and reimbursement complexities, which ultimately slow progress for improving access. While reimbursement barriers exist for digital therapeutics, ongoing legislative efforts, development of private payer frameworks, and programs&hellip;<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[995],"tags":[],"content-categories":[996],"class_list":["post-33231","post","type-post","status-publish","format-standard","hentry","category-news","content-categories-digital-health","entry","no-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>An Access Path for Digital Therapeutics | Avalere Health Advisory<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"An Access Path for Digital Therapeutics | Avalere Health Advisory\" \/>\n<meta property=\"og:description\" content=\"While there has been substantial investment in and focus on the digital health sector, patient access to digital therapeutics (DTx) remains hindered by numerous obstacles, such as regulatory and reimbursement complexities, which ultimately slow progress for improving access. While reimbursement barriers exist for digital therapeutics, ongoing legislative efforts, development of private payer frameworks, and programs&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"Avalere Health Advisory\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-03T18:56:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-03T19:07:28+00:00\" \/>\n<meta name=\"author\" content=\"mgomez@avalere.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@avalerehealth\" \/>\n<meta name=\"twitter:site\" content=\"@avalerehealth\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mgomez@avalere.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"An Access Path for Digital Therapeutics | Avalere Health Advisory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics","og_locale":"en_US","og_type":"article","og_title":"An Access Path for Digital Therapeutics | Avalere Health Advisory","og_description":"While there has been substantial investment in and focus on the digital health sector, patient access to digital therapeutics (DTx) remains hindered by numerous obstacles, such as regulatory and reimbursement complexities, which ultimately slow progress for improving access. While reimbursement barriers exist for digital therapeutics, ongoing legislative efforts, development of private payer frameworks, and programs&hellip;","og_url":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics","og_site_name":"Avalere Health Advisory","article_published_time":"2024-07-03T18:56:10+00:00","article_modified_time":"2024-10-03T19:07:28+00:00","author":"mgomez@avalere.com","twitter_card":"summary_large_image","twitter_creator":"@avalerehealth","twitter_site":"@avalerehealth","twitter_misc":{"Written by":"mgomez@avalere.com","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics#article","isPartOf":{"@id":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics"},"author":{"name":"mgomez@avalere.com","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/61d345e49f3e41ed120bded81755741f"},"headline":"An Access Path for Digital Therapeutics","datePublished":"2024-07-03T18:56:10+00:00","dateModified":"2024-10-03T19:07:28+00:00","mainEntityOfPage":{"@id":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics"},"wordCount":191,"commentCount":0,"publisher":{"@id":"https:\/\/advisory.avalerehealth.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics#respond"]}]},{"@type":"WebPage","@id":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics","url":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics","name":"An Access Path for Digital Therapeutics | Avalere Health Advisory","isPartOf":{"@id":"https:\/\/advisory.avalerehealth.com\/#website"},"datePublished":"2024-07-03T18:56:10+00:00","dateModified":"2024-10-03T19:07:28+00:00","breadcrumb":{"@id":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/advisory.avalerehealth.com\/news\/an-access-path-for-digital-therapeutics#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/advisory.avalerehealth.com\/"},{"@type":"ListItem","position":2,"name":"An Access Path for Digital Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/advisory.avalerehealth.com\/#website","url":"https:\/\/advisory.avalerehealth.com\/","name":"Avalere Health Advisory","description":"","publisher":{"@id":"https:\/\/advisory.avalerehealth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/advisory.avalerehealth.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/advisory.avalerehealth.com\/#organization","name":"Avalere Health","url":"https:\/\/advisory.avalerehealth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/logo\/image\/","url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2025\/03\/avalere-health-logo-cropped-white_1x.webp","contentUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2025\/03\/avalere-health-logo-cropped-white_1x.webp","width":433,"height":47,"caption":"Avalere Health"},"image":{"@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/avalerehealth"]},{"@type":"Person","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/61d345e49f3e41ed120bded81755741f","name":"mgomez@avalere.com","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8d995fcf31bf764c9e82a7d6f0f67fd5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8d995fcf31bf764c9e82a7d6f0f67fd5?s=96&d=mm&r=g","caption":"mgomez@avalere.com"},"url":"https:\/\/advisory.avalerehealth.com\/author\/mgomezavalere-com"}]}},"_links":{"self":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/33231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/comments?post=33231"}],"version-history":[{"count":2,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/33231\/revisions"}],"predecessor-version":[{"id":33235,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/33231\/revisions\/33235"}],"wp:attachment":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/media?parent=33231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/categories?post=33231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/tags?post=33231"},{"taxonomy":"content-categories","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/content-categories?post=33231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}